Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.60 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.54 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | OGA | O60502 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131480 | 0.88 | REV1 (0.57) | HRH3 | |
| SCHEMBL19266658 | 0.87 | HRH3 (0.54) | HRH3PRMT5WDR77L3MBTL1OGA | |
| SCHEMBL5128246 | 0.87 | HRH3 (0.60) | HRH3PRMT5WDR77L3MBTL1OGA | |
| SCHEMBL5128540 | 0.84 | OGA (0.55) | PRMT5WDR77OGACARM1CYP2D6 | |
| SCHEMBL15131063 | 0.83 | OGA (0.56) | PRMT5WDR77OGA | |
| SCHEMBL5131372 | 0.81 | HRH3 (0.51) | HRH3PRMT5WDR77L3MBTL1OGA | |
| SCHEMBL5128323 | 0.78 | OGA (0.51) | PRMT5WDR77OGA | |
| SCHEMBL30509641 | 0.77 | HRH3 (0.50) | HRH3PRMT5WDR77BCHE | |
| SCHEMBL5120634 | 0.77 | OGA (0.50) | HRH3PRMT5WDR77L3MBTL1OGA | |
| SCHEMBL5130916 | 0.76 | REV1 (0.65) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | claimed |
| WO-2005077903-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED TETRAHYDROISOQUINOLINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-08-25 | — | — | WO | claimed |
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | disclosed |
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | disclosed |
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | MCHR1, MCHR2, MC1R | HRH3 88/4885PRMT5 242/4885WDR77 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.